Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 13/20 | 0.66 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.45 |
| ▸ | CDC7 | O00311 | 4/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.45 |
| ▸ | CDK2 | P24941 | 4/20 | 0.45 |
| ▸ | GSK3B | P49841 | 4/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.45 |
| ▸ | PRKACA | P17612 | 3/20 | 0.45 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | PRKX | P51817 | 1/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851795 | 0.87 | CHEK1 (0.64) | CHEK1ROCK2CDC7MAP4K4CDK2 | |
| SCHEMBL4848090 | 0.86 | CHEK1 (0.63) | CHEK1ROCK2CDC7MAP4K4CDK2 | |
| SCHEMBL4857380 | 0.86 | CHEK1 (0.63) | CHEK1ROCK2CDC7MAP4K4CDK2 | |
| SCHEMBL4856364 | 0.86 | CHEK1 (0.65) | CHEK1ROCK2CDC7MAP4K4CDK2 | |
| SCHEMBL4848940 | 0.85 | CHEK1 (0.61) | CHEK1ROCK2CDC7MAP4K4CDK2 | |
| SCHEMBL4854189 | 0.85 | CHEK1 (0.61) | CHEK1ROCK2CDC7MAP4K4CDK2 | |
| SCHEMBL4855156 | 0.84 | CHEK1 (0.74) | CHEK1ROCK2CDC7MAP4K4CDK2 | |
| SCHEMBL4856777 | 0.81 | CHEK1 (0.63) | CHEK1ROCK2CDC7MAP4K4CDK2 | |
| SCHEMBL4856938 | 0.81 | CHEK1 (0.59) | CHEK1ROCK2CDC7MAP4K4CDK2 | |
| SCHEMBL4856795 | 0.81 | CHEK1 (0.75) | CHEK1ROCK2CDK2GSK3BIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | claimed |
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | CHEK1 38/4885ROCK2 483/4885CDC7 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.